BioLineRx (BLRX)
(Real Time Quote from BATS)
$0.66 USD
+0.01 (1.41%)
Updated Sep 20, 2024 12:09 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 141 - 160 ( 205 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
BioLineRX and Novartis Team Up; Important Validation; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
BL-8040 Program Expanding, So''s Our Target; Price Target Upped to $10.50
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Expanding BL-8040''s Profile With Three Collaborative Studies
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
You Got To Move It, Move It (and Kill It); BL-8040 Data Impress
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
3Q14 Results; Ready for Catalysts? We Are; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Potential Accelerated Path; ''7010 Could Be Device in EU; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Superb Safety Profile for ''8040; More Cohorts Being Added; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Positive 2010 BCM Pilot Study Bodes Well for PRESERVATION; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Healthcare - Potential Short-term Weakness in AML, but Approaches Are Differentiated
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
$410M Ambit Acquisition Bodes Well After ''8040 + Quizartinib Show Synergy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.